Department of Urology, Copenhagen University Hospital - Herlev & Gentofte Hospital, Gentofte, Denmark.
Department of Urology, Copenhagen University Hospital - Herlev & Gentofte Hospital, Gentofte, Denmark; Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.
Scand J Urol. 2024 Oct 4;59:169-172. doi: 10.2340/sju.v59.41991.
In high-risk patients, prostatic stents may alleviate obstruction at the prostate level. Since 2020 we have used thermo-expandable intraprostatic nitinol stents. Here we document outcomes through the first years with the procedure.
We reviewed patients who had undergone stent treatment between May 2020 and October 2023. Patient and procedural data, urinary symptoms, complications and side effects were recorded. Descriptive statistics were used to summarize outcomes and we evaluated predictors of success and complications using robust multiple regression analyses.
We included 52 consecutive patients with a median age of 82 years (range 71-96) and a median Charlson Comorbidity Index of 6 (3-11). Forty-seven men used indwelling catheters, two used clean intermittent catheterization, and three had severe lower urinary tract symptoms. Stents were placed under general anesthesia, sedation, and local anesthesia in 39, 4, and 9 men, respectively. The median treatment time was 14 min (range 8-40). One complication, in the form of an infection requiring IV antibiotics, occurred. Subsequently, 45 men (87%) were able to void spontaneously without bothersome symptoms. After a median of 11 (2-44) months, 8 men had their stents removed due to recurring symptoms. This gives an overall success rate of 37/52 patients (71%). No predictors of success or complications were identified.
Thermo-expandable intraprostatic nitinol stents demonstrate a high success rate with a low risk of complications and may serve as an alternative to permanent or intermittent catheterization for men who are unable or unwilling to undergo flow-improving surgery.
在高危患者中,前列腺支架可能会缓解前列腺水平的梗阻。自 2020 年以来,我们一直使用热可膨胀的前列腺内镍钛诺支架。在此,我们通过该手术的头几年记录了结果。
我们回顾了 2020 年 5 月至 2023 年 10 月期间接受支架治疗的患者。记录了患者和手术过程数据、尿症状、并发症和副作用。使用描述性统计来总结结果,并使用稳健的多元回归分析评估成功和并发症的预测因素。
我们纳入了 52 例连续患者,中位年龄为 82 岁(范围为 71-96 岁),中位 Charlson 合并症指数为 6(3-11)。47 名男性使用留置导尿管,2 名男性使用间歇性清洁导尿,3 名男性有严重的下尿路症状。支架分别在全身麻醉、镇静和局部麻醉下放置,分别有 39、4 和 9 名男性。中位治疗时间为 14 分钟(范围为 8-40 分钟)。发生 1 例并发症,表现为需要静脉使用抗生素的感染。随后,45 名男性(87%)能够自行排尿,没有明显症状。中位随访 11 个月(范围为 2-44 个月)后,8 名男性因症状复发而取出支架。因此,52 名患者中有 37 名(71%)整体成功。未发现成功或并发症的预测因素。
热可膨胀前列腺内镍钛诺支架具有较高的成功率,并发症风险较低,对于不能或不愿意接受改善尿流手术的男性,可作为永久性或间歇性导尿的替代方法。